Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 27 Jun 2019 Planned initiation date changed from 1 Feb 2019 to 1 Jul 2019.
- 10 Jan 2019 Planned End Date changed from 1 Dec 2024 to 1 Feb 2025.
- 10 Jan 2019 Planned primary completion date changed from 1 Dec 2022 to 1 Feb 2023.